Page 9 - Trinity Life Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Drug companies look to AI to end 'hit and miss' research Julia Kollewe © Provided by The Guardian Photograph: Sakchai Lalit/AP The hunt for new medicines has often been more like a game of roulette than high-end science. But now the pharmaceutical sector is on the cusp of a transformation, as it delves into cutting-edge technology to come up with new treatments for diseases such as cancer, rheumatoid arthritis and Alzheimer’s. Artificial intelligence (AI) is set to improve the industry’s success rates and speed up drug discovery, potentially saving it billions of dollar...

Share this article Share this article ResearchAndMarkets.com's offering. Cell and Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global cell & gene therapy market. Major players in the cell and gene therapy market are Gilead Sciences, Bristol-Myers Squibb, Novartis AG, Amgen, Merck, Organogenesis Holdings, Dendreon, Vericel, Bluebird Bio and Fibrocell Science. The global cell and gene therapy market is expected to decline from $6.68 billion in 2019 to $6.92 b...

Is pharma putting all of its eggs in one COVID basket? 16th December 2020 The pharmaceutical industry’s reputation has undoubtedly been enhanced by its response to COVID-19. The sector has been buoyed by the vaccine launch and distribution news, plus previous research, treatment and testing, backed by impressive cross-sector partnerships. All of these highly visibly outcomes have presented the sector as responding rapidly to a wider societal need and having put aside competitive differences for the common good. Pharma's reputation However, one concern for the industry, which I will go on t...